Compare The Coca-Cola Co K (KO) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs McKesson Corporation — how do they compare? The Coca-Cola Co K trades at $81.9 (market cap $353.32B), while McKesson Corporation trades at $829.95 (market cap $97.35B). The key difference: The Coca-Cola Co K is far larger — about 3.6× McKesson Corporation's market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | MCK | |
|---|---|---|
Market Cap | $353.32B | $97.35B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $995.69 |
52-Week Low | $65.67 | $659.01 |
Enterprise Value | $383.39B | $101.98B |
Dividend Yield | 2.58% | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.56, down 3.96% on the day, with a bearish technical signal but strong fundamentals including a 27.8% net income margin and consistent earnings beats. Recent news highlights institutional accumulation and steady dividend payments. The stock is supported by robust cash flow and brand strength, though near-term price action shows weakness below key resistance.
Outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include regional demand divergence and high debt levels. The stock presents a value opportunity for dividend-focused investors given its 64-year dividend growth streak, but macroeconomic pressures warrant caution.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
